4.7 Article

Efficient on-chip isolation of HIV subtypes

Journal

LAB ON A CHIP
Volume 12, Issue 8, Pages 1508-1515

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/c2lc20706k

Keywords

-

Funding

  1. W. H. Coulter Foundation [RO1 A1081534, R21 AI087107]
  2. Center for Integration of Medicine and Innovative Technology (CIMIT) under U.S. Army [DAMD17-02-2-0006, W81XWH-07-2-0011, W81XWH-09-2-0001]
  3. U.S. Army Medical Research & Materiel Command (USAMRMC)
  4. Telemedicine & Advanced Technology Research Center (TATRC), at Fort Detrick, MD

Ask authors/readers for more resources

HIV has caused a global pandemic over the last three decades. There is an unmet need to develop point-of-care (POC) viral load diagnostics to initiate and monitor antiretroviral treatment in resource-constrained settings. Particularly, geographical distribution of HIV subtypes poses significant challenges for POC immunoassays. Here, we demonstrated a microfluidic device that can effectively capture various subtypes of HIV particles through anti-gp120 antibodies, which were immobilized on the microchannel surface. We first optimized an antibody immobilization process using fluorescent antibodies, quantum dot staining and AFM studies. The results showed that anti-gp120 antibodies were immobilized on the microchannel surface with an elevated antibody density and uniform antibody orientation using a Protein G-based surface chemistry. Further, RT-qPCR analysis showed that HIV particles of subtypes A, B and C were captured repeatably with high efficiencies of 77.2 +/- 13.2%, 82.1 +/- 18.8, and 80.9 +/- 14.0% from culture supernatant, and 73.2 +/- 13.6, 74.4 +/- 14.6 and 78.3 +/- 13.3% from spiked whole blood at a viral load of 1000 copies per mL, respectively. HIV particles of subtypes A, B and C were captured with high efficiencies of 81.8 +/- 9.4%, 72.5 +/- 18.7, and 87.8 +/- 3.2% from culture supernatant, and 74.6 +/- 12.9, 75.5 +/- 6.7 and 69.7 +/- 9.5% from spiked whole blood at a viral load of 10 000 copies per mL, respectively. The presented immuno-sensing device enables the development of POC on-chip technologies to monitor viral load and guide antiretroviral treatment (ART) in resource-constrained settings.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available